KISQALI, also known by its generic name ribociclib, is a prescription medication used in the treatment of certain types of breast cancer. Specifically, it is indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. KISQALI works as a CDK4/6 inhibitor, a class of drugs that help slow down the progression of cancer by inhibiting the activity of cyclin-dependent kinases 4 and 6. These enzymes are involved in the proliferation of cancer cells. Typically, KISQALI is used in combination with an aromatase inhibitor or fulvestrant as part of a targeted therapy approach. Its use is aimed at postmenopausal women, but it can also be prescribed to men and premenopausal women under certain conditions. As with any cancer treatment, the use of KISQALI is associated with specific side effects, and its administration should be closely monitored by a healthcare professional.